Intradermal <i>Phleum pratense</i> allergoid immunotherapy. Double‐blind, randomized, placebo‐controlled trial

Martínez, Francisco Javier Solá; Jiménez, Ruth María Barranco; García, Camino López; Sanchez, C. Senent; Guerra, Carlos Blanco; Fernández‐Rivas, Montserrat; Castro, Arantza Vega; González, Ignacio Dávila; Martínez, Antonio Carbonell; Bravo, Carmen; Torrijos, Elisa Gómez; Gil, David; Peláez, Ricardo Palacios

doi:10.1111/cea.13740

Cited by 9 publications

(8 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Only two double-blinded placebo-controlled trials with conflicting results have been conducted regarding IDIT ( 30 31 ). The first of these studies reported that daily combined symptom-medication scores (CSMSs) in the active group, a parameter strongly recommended as a primary end point in evaluating the treatment efficacy of AIT, did not differ from daily CSMSs in the placebo group ( 30 ) ( Fig.…”

Section: Therapeutic Efficacy Of Aits With Alternative Routes Of Admi...mentioning

confidence: 99%

“…The small quantity of allergen (7 ng of the major allergen Phl p 5) in a small volume (20 μL) may further induce Th2 rather than Th1 or Treg immunity, resulting in low therapeutic efficacy, although intradermal injection of allergens may promote drainage of allergens into LNs. Conversely, the second study found that IDIT reduced CSMSs and serum allergen-specific IgE levels, while increasing allergen tolerance in the conjunctival provocation test ( 31 ). In both studies, grass pollen allergens ( Phleum pratense ) were injected weekly in six total administrations.…”

Section: Therapeutic Efficacy Of Aits With Alternative Routes Of Admi...mentioning

confidence: 99%

“…Treatment-emergent adverse events (TEAEs) associated with IDIT, EPIT, and ILIT are shown in Fig. 2B ( 11 17 19 20 23 26 27 30 31 33 34 36 37 38 39 40 41 42 43 47 48 50 51 55 ). Compared with the placebo group, the risk of TEAEs did not increase in the IDIT group (risk ratio, 1.03; 95% CI, 0.72–1.48; p=0.87; I 2 =0%) or EPIT group (risk ratio, 1.48; 95% CI, 0.81–2.72; p=0.20; I 2 =98%).…”

Section: Safety Of Aits With Alternative Routes Of Administrationmentioning

confidence: 99%

See 2 more Smart Citations

Recent Advances in Allergen-Specific Immunotherapy in Humans: A Systematic Review

et al. 2022

View full text Add to dashboard Cite

Allergen-specific immunotherapy (AIT) is presumed to modulate the natural course of allergic disease by inducing immune tolerance. However, conventional AITs, such as subcutaneous immunotherapy and sublingual immunotherapy, require long treatment durations and often provoke local or systemic hypersensitivity reactions. Therefore, only <5% of allergy patients receive AIT as second-line therapy. Novel administration routes, such as intralymphatic, intradermal and epicutaneous immunotherapies, and synthetic recombinant allergen preparations have been evaluated to overcome these limitations. We will review the updated views of diverse AIT methods, and discuss the limitations and opportunities of the AITs for the treatment of allergic diseases in humans.

show abstract

Section: Therapeutic Efficacy Of Aits With Alternative Routes Of Admi...mentioning

confidence: 99%

Section: Therapeutic Efficacy Of Aits With Alternative Routes Of Admi...mentioning

confidence: 99%

Section: Safety Of Aits With Alternative Routes Of Administrationmentioning

confidence: 99%

See 1 more Smart Citation

Recent Advances in Allergen-Specific Immunotherapy in Humans: A Systematic Review

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Allergoids are modified allergen extracts whose allergenicity has been reduced with preserved immunogenic activity [ 36 ]. Allergoids are commonly administered subcutaneously; however, Martinez et al [ 37 ] conducted the first randomized controlled trial (RCT) in IDIT using P. pratense allergoid with a satisfactory result. Subjects were randomized to receive six intradermal weekly injections of placebo, low-dose allergoid, or high-dose allergoid.…”

Section: Modified Formulations Of Intradermal Immunotherapymentioning

confidence: 99%

Intradermal Allergen Immunotherapy for Allergic Rhinitis: Current Evidence

Atipas

Kanjanawasee

Tantilipikorn

2022

JPM

View full text Add to dashboard Cite

Allergic rhinitis (AR) is an immunoglobulin E (IgE)-mediated inflammatory disease that is induced by allergen introduction to the nasal mucosa, which triggers an inflammatory response. The current treatments for AR include allergen avoidance and pharmacotherapy; however, allergen-specific immunotherapy (AIT) is the only treatment that can be employed to modify immunologic responses and to achieve a cure for allergic diseases. The current standard routes of AIT administration are the subcutaneous and sublingual routes. Alternatively, the dermis contains a high density of dermal dendritic cells that act as antigen-presenting cells, so intradermal administration may confer added advantages and increase the efficacy of AIT. Moreover, intradermal immunotherapy (IDIT) may facilitate a reduction in the allergen dosage and a shortening of the treatment duration. The aim of this review was to search and evaluate the current evidence specific to IDIT, including its modified formulations, such as allergoids and peptides. The results of this review reveal conflicting evidence that suggests that the overall benefit of IDIT remains unclear. As such, further clinical trials are needed to establish the clinical utility of IDIT, and to determine the optimal treatment-related protocols.

show abstract

“…A new tool for assessing quality of life called RAPP was developed and shows promise for combining quality of life assessment for asthma and rhinitis 21 . Intervention trials included a new form of nasal steroid and a new form of grass pollen immunotherapy 22‐24 …”

Section: Rhinitismentioning

confidence: 99%

Developments in the field of allergy in 2020 through the eyes of Clinical and Experimental Allergy

Boyle

Shamji

2021

Clin Experimental Allergy

View full text Add to dashboard Cite

show abstract

Intradermal Phleum pratense allergoid immunotherapy. Double‐blind, randomized, placebo‐controlled trial

Abstract: This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

Cited by 9 publications

References 29 publications

Recent Advances in Allergen-Specific Immunotherapy in Humans: A Systematic Review

Recent Advances in Allergen-Specific Immunotherapy in Humans: A Systematic Review

Intradermal Allergen Immunotherapy for Allergic Rhinitis: Current Evidence

Developments in the field of allergy in 2020 through the eyes of Clinical and Experimental Allergy

Contact Info

Product

Resources

About